Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).
Hiroshige Yoshioka
Honoraria - AstraZeneca
Tetsuya Mitsudomi
Honoraria - AstraZeneca
Satoshi Morita
Honoraria - AstraZeneca
Yasushi Yatabe
Honoraria - DAKO; Leica Biosystems; Pfizer; Roche; Ventana
Shunichi Negoro
No relevant relationships to disclose
Isamu Okamoto
No relevant relationships to disclose
Takashi Seto
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca
Miyako Satouchi
Honoraria - AstraZeneca; Sanofi
Hirohito Tada
No relevant relationships to disclose
Tomonori Hirashima
No relevant relationships to disclose
Kazuhiro Asami
No relevant relationships to disclose
Nobuyuki Katakami
Honoraria - AstraZeneca; Sanofi
Minoru Takada
No relevant relationships to disclose
Kazuhiko Shibata
No relevant relationships to disclose
Shinzoh Kudoh
Research Funding - Kyowa Hakko Kirin
Eiji Shimizu
No relevant relationships to disclose
Hiroshi Saito
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Shinichi Toyooka
Honoraria - AstraZeneca
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca; Sanofi
Masahiro Fukuoka
No relevant relationships to disclose